First National Trust Co Sells 2,017 Shares of Johnson & Johnson $JNJ

First National Trust Co trimmed its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 1.4% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 139,641 shares of the company’s stock after selling 2,017 shares during the quarter. Johnson & Johnson comprises about 0.8% of First National Trust Co’s investment portfolio, making the stock its 26th largest holding. First National Trust Co’s holdings in Johnson & Johnson were worth $21,330,000 at the end of the most recent quarter.

Several other hedge funds also recently made changes to their positions in the business. Brighton Jones LLC increased its holdings in Johnson & Johnson by 13.9% in the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock valued at $7,502,000 after buying an additional 6,332 shares during the period. Wealth Group Ltd. bought a new position in Johnson & Johnson in the first quarter valued at approximately $218,000. Jaffetilchin Investment Partners LLC increased its stake in shares of Johnson & Johnson by 1.9% in the 1st quarter. Jaffetilchin Investment Partners LLC now owns 36,300 shares of the company’s stock valued at $6,020,000 after purchasing an additional 685 shares during the last quarter. Philip James Wealth Mangement LLC increased its stake in shares of Johnson & Johnson by 1.7% in the 1st quarter. Philip James Wealth Mangement LLC now owns 77,415 shares of the company’s stock valued at $12,839,000 after purchasing an additional 1,257 shares during the last quarter. Finally, Achmea Investment Management B.V. increased its stake in shares of Johnson & Johnson by 15.7% in the 1st quarter. Achmea Investment Management B.V. now owns 248,227 shares of the company’s stock valued at $41,166,000 after purchasing an additional 33,641 shares during the last quarter. 69.55% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of research firms have issued reports on JNJ. Guggenheim upgraded Johnson & Johnson from a “neutral” rating to a “buy” rating and lifted their target price for the company from $167.00 to $206.00 in a research report on Tuesday, September 23rd. Cowen reaffirmed a “buy” rating on shares of Johnson & Johnson in a report on Tuesday, October 14th. Bank of America boosted their target price on shares of Johnson & Johnson from $198.00 to $204.00 and gave the stock a “neutral” rating in a research note on Wednesday, October 15th. Wall Street Zen raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a research note on Saturday, September 13th. Finally, Raymond James Financial boosted their price objective on Johnson & Johnson from $174.00 to $209.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 15th. Three research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have given a Hold rating to the company’s stock. According to MarketBeat, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and an average target price of $199.05.

Insider Activity

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the stock in a transaction that occurred on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the transaction, the executive vice president directly owned 178,013 shares in the company, valued at approximately $31,652,491.53. This represents a 24.08% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Trading Down 0.0%

NYSE JNJ opened at $190.31 on Tuesday. The business’s 50-day moving average price is $182.54 and its two-hundred day moving average price is $166.65. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $194.48. The firm has a market capitalization of $458.50 billion, a PE ratio of 18.37, a price-to-earnings-growth ratio of 2.24 and a beta of 0.40. The company has a current ratio of 1.07, a quick ratio of 0.80 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. The company had revenue of $24.02 billion for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. On average, analysts expect that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th will be given a dividend of $1.30 per share. The ex-dividend date is Tuesday, November 25th. This represents a $5.20 annualized dividend and a dividend yield of 2.7%. Johnson & Johnson’s dividend payout ratio is presently 50.19%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.